Similarly in a different study, Chk2 depletion reduced the platinum sensitivity of ovarian cancer cell lines, indicating that Chk2 should not be used as a therapeutic target in HGSOC patients because it eliminated the cisplatin-induced S-phase cell cycle arrest and increased long-term survival resistance to cisplatin [37]. This evidence concerns the gene CHEK2 and ovarian carcinoma.